Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00345865 · OUTCOME

Number of Participants With 1 Year Progression Free Survival

Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma · Source last updated 2020-07-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
1 year

What was measured

Progression is defined using the Response Criteria for Non-Hodgkin's Lymphoma given by NCI Sponsored International Working Group.The definition is as follows: At least a 50% increase from nadir of any previously identified abnormal node. Appearance of any new lesion during or at the end of therapy.

Groups in this outcome

NHL With Irradiation

Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.

HL Without Irradiation

Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.

NHL - HIV Infected With Irradiation

Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.

NHL - HIV Infected Without Irradiation

Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.

NHL Without Radiation and Cyclophosphamide

Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
NHL With Irradiation171
HL Without Irradiation149
NHL - HIV Infected With Irradiation2
NHL - HIV Infected Without Irradiation5
NHL Without Radiation and Cyclophosphamide146

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
NHL With Irradiation112Not reportedNot reportedNot reportedNot reported
HL Without Irradiation102Not reportedNot reportedNot reportedNot reported
NHL - HIV Infected With Irradiation1Not reportedNot reportedNot reportedNot reported
NHL - HIV Infected Without Irradiation2Not reportedNot reportedNot reportedNot reported
NHL Without Radiation and Cyclophosphamide116Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        112
      2. group Id
        OG001
        value
        102
      3. group Id
        OG002
        value
        1
      4. group Id
        OG003
        value
        2
      5. group Id
        OG004
        value
        116
denoms
  1. counts
    1. group Id
      OG000
      value
      171
    2. group Id
      OG001
      value
      149
    3. group Id
      OG002
      value
      2
    4. group Id
      OG003
      value
      5
    5. group Id
      OG004
      value
      146
    units
    Participants
description
Progression is defined using the Response Criteria for Non-Hodgkin's Lymphoma given by NCI Sponsored International Working Group.The definition is as follows: At least a 50% increase from nadir of any previously identified abnormal node. Appearance of any new lesion during or at the end of therapy.
groups
  1. description
    Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
    id
    OG000
    title
    NHL With Irradiation
  2. description
    Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
    id
    OG001
    title
    HL Without Irradiation
  3. description
    Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
    id
    OG002
    title
    NHL - HIV Infected With Irradiation
  4. description
    Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
    id
    OG003
    title
    NHL - HIV Infected Without Irradiation
  5. description
    Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
    id
    OG004
    title
    NHL Without Radiation and Cyclophosphamide
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
1 year
title
Number of Participants With 1 Year Progression Free Survival
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice